Please login to the form below

Not currently logged in
Email:
Password:

Novartis Oncology head Bruno Strigini to retire

Will leave the Swiss pharma firm, and the industry, next year

Novartis Bruno StriginiThe head of Novartis Oncology Bruno Strigini is set to step down and retire from the pharmaceutical industry.

Citing personal reasons, the Swiss pharma firm said Strigini would step back from his place on its executive committee by December 31 and leave his current role in early 2018.

Novartis CEO Joseph Jimenez said: "I'd like to thank Bruno Strigini for his contributions and achievements. He has navigated the business unit through the Gleevec patent expiration and has led the successful integration of the GSK Oncology Product Portfolio acquired in 2015. I wish him the best for his future."

Strigini joined Novartis in 2014 from Merck & Co, where he spent nearly five years as president, Europe and Canada.

Prior to that he served in a similar role at Schering-Plough, before its acquisition by Merck in 2009.

19th December 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics